Gilead Sciences Inc (GILD) Q4 2021 (USD): Adj. EPS 0.69 (exp. 1.59), Revenue 7.20bln (exp. 6.66bln)
- Adj. product GM 70.5%.
- Veklury revenue 1.36bln (exp. 0.79bln).
- Trodelvy revenue 118mln (exp. 120mln).
GUIDANCE
- FY adj. EPS view 6.20-6.70 (exp. 6.89), revenue view 7.24bln (exp. 24.37bln).
- Product sales view 23.8-24.3bln.
- Veklury revenue view 2bln (exp. 1.52bln)
NEWS
- GlaxoSmihKline (GSK LN) announced a settlement between Viiv healthcare and Gilead (GILD) that resolves litigation relating to Biktarvy and VIIV's Dolutegravir patents and entry into a patent licence agreement.
- GILD will make an up front payment of USD 1.25bln to VIIV in Q1 22 and a 3% royalty on future US sales of Biktarvy.
Via businesswire
01 Feb 2022 - 21:01- Equities- Source: businesswire
Subscribe Now to Newsquawk
Click here for a 1 week free trial
Newsquawk provides audio news and commentary for over 15,000professional traders and brokers worldwide. Services include:
- Real-time audio coverage from 0630 to 2200 London time plus Asia-Pac 2200 to 1000 London time
- Teams of analysts covering equities, fixed income, FX, energy, and metals markets
- Real-time scrolling news service with instant analysis
- Daily and weekly pre-market research and calendars
- Video updates covering near-term key risk events & primary trading themes
- One-to-one chat with our expert analysts